QNCX Quince Therapeutics, Inc.
Nasdaq · SEC CIK 1662774 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $173.5K 1 sales by 1 insiders
- Filings on record
- 111 since 2021-07-07, latest 2026-06-15 17:57
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Benatti Luca | Dir | — | $173.5K |
| Hannah Brendan | COO, CCO, CBO | — | — |
| Thye Dirk | CEO, CMO, Dir | — | — |
Transactions 59
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-29 | 2024-10-23 | QNCX | Benatti Luca | Dir | J - Other | — | +8,918 | 89.2K | +11% | — | |
| 2025-12-29 | 2025-12-26 | QNCX | Benatti Luca | Dir | S - Sale | $3.47 | -50.0K | 39.2K | -56% | -$173.5K | |
| 2025-12-12 | 2025-12-10 | QNCX | Thye Dirk | CEO, CMO, Dir | G - Gift | $0.00 | -739.9K | 255.0K | -74% | $0 | |
| I | 2025-12-12 | 2025-12-10 | QNCX | Thye Dirk | CEO, CMO, Dir | G - Gift | $0.00 | +739.9K | 739.9K | New | $0 |
| DM | 2025-12-08 | 2025-12-05 | QNCX | Hannah Brendan | COO, CCO, CBO | M - OptEx | $0.9079 | +27.6K | 336.5K | +9% | +$25.0K |
| D | 2025-06-23 | 2025-06-18 | QNCX | Hannah Brendan | COO, CCO, CBO | A - Grant | $1.20 | +37.7K | 334.3K | +13% | +$45.3K |
| D | 2025-06-23 | 2025-06-18 | QNCX | Ryan Charles S. | Pres | A - Grant | $1.20 | +7,548 | 130.0K | +6% | +$9,058 |
| D | 2025-06-23 | 2025-06-18 | QNCX | Thye Dirk | CEO, CMO, Dir | A - Grant | $1.20 | +150.9K | 994.9K | +18% | +$181.1K |
| M | 2024-09-03 | 2024-08-29+ | QNCX | Thye Dirk | CEO AND Chief MEDICAL Off, Dir | P - Purchase | $0.695 | +154.5K | 843.9K | +22% | +$107.4K |
| 2024-08-22 | 2024-08-20 | QNCX | Ryan Charles S. | Pres | P - Purchase | $0.65 | +48.4K | 122.5K | +65% | +$31.5K | |
| M | 2024-08-21 | 2024-08-19+ | QNCX | Hannah Brendan | Chief BUSINESS Off. AND COO | P - Purchase | $0.6209 | +38.9K | 265.7K | +17% | +$24.2K |
| D | 2024-06-05 | 2024-06-04 | QNCX | Hannah Brendan | Chief BUSINESS Off. AND COO | M - OptEx | $0.55 | +56.1K | 257.6K | +28% | +$30.8K |
| DM | 2024-01-17 | 2024-01-16 | QNCX | Thye Dirk | CEO, Dir | M - OptEx | $0.7932 | +240.5K | 539.4K | +80% | +$190.8K |
| MI | 2023-12-14 | 2023-12-12+ | QNCX | Lamond David | Dir | P - Purchase | $1.02 | +45.6K | 2.32M | +2% | +$46.5K |
| 2023-12-14 | 2023-12-12 | QNCX | Lamond David | Dir | P - Purchase | $1.02 | +22.3K | 2.30M | +1.0% | +$22.8K | |
| MI | 2023-12-07 | 2023-12-05+ | QNCX | Lamond David | Dir | P - Purchase | $1.01 | +57.4K | 2.28M | +3% | +$58.1K |
| MI | 2023-12-01 | 2023-11-29+ | QNCX | Lamond David | Dir | P - Purchase | $0.94 | +43.1K | 2.19M | +2% | +$40.5K |
| MI | 2023-08-31 | 2023-08-30+ | QNCX | Lamond David | Dir | P - Purchase | $1.31 | +82.1K | 2.14M | +4% | +$107.9K |
| MI | 2023-08-17 | 2023-08-15+ | QNCX | Lamond David | Dir | P - Purchase | $1.30 | +250.0K | 2.10M | +14% | +$325.7K |
| 2023-08-11 | 2023-08-10 | QNCX | Thye Dirk | CEO, Dir | P - Purchase | $1.26 | +88.0K | 448.9K | +24% | +$110.9K | |
| 2023-08-09 | 2023-08-08 | QNCX | McLoughlin Margaret | Dir | P - Purchase | $1.23 | +8,000 | 8,000 | New | +$9,840 | |
| 2023-08-09 | 2023-08-08 | QNCX | Hannah Brendan | Chief Business Off | P - Purchase | $1.22 | +71.8K | 201.6K | +55% | +$87.5K | |
| 2023-08-09 | 2023-08-08 | QNCX | Thye Dirk | CEO, Dir | P - Purchase | $1.24 | +80.0K | 360.9K | +28% | +$99.2K | |
| 2023-03-06 | 2023-03-06 | QNCX | Monohon Ted | CAO, VP | S - Sale | $0.98 | -1,871 | 27.4K | -6% | -$1,834 | |
| 2022-12-07 | 2022-12-05 | QNCX | Monohon Ted | CAO, VP | F - Tax | $0.72 | -1,640 | 29.3K | -5% | -$1,181 | |
| 2022-09-08 | 2022-09-06 | QNCX | Monohon Ted | CAO, VP | F - Tax | $1.64 | -1,520 | 31.0K | -5% | -$2,493 | |
| 2022-06-08 | 2022-06-06 | QNCX | McDowell Caryn Gordon | Chief Legal, Adm. Off | F - Tax | $2.86 | -6,700 | 133.3K | -5% | -$19.2K | |
| 2022-06-08 | 2022-06-06 | QNCX | McDowell Caryn Gordon | Chief Legal, Adm. Off | S - Sale | $2.86 | -10.8K | 122.5K | -8% | -$30.9K | |
| 2022-06-08 | 2022-06-06 | QNCX | Monohon Ted | CAO, VP | F - Tax | $3.12 | -1,529 | 32.5K | -4% | -$4,770 | |
| 2022-06-08 | 2022-06-06 | QNCX | Holsinger Leslie | EVP, Preclinical Development | F - Tax | $2.86 | -10.9K | 148.1K | -7% | -$31.2K | |
| A | 2022-05-27 | 2022-05-19 | QNCX | Smith Karen L. | Chief Medical Off | A - Grant | $0.00 | +170.4K | 194.7K | +700% | $0 |
| A | 2022-05-27 | 2022-05-19 | QNCX | Hannah Brendan | Chief Business Off | A - Grant | $0.00 | +113.6K | 129.8K | +700% | $0 |
| A | 2022-05-27 | 2022-05-19 | QNCX | Thye Dirk | CEO, Dir | A - Grant | $0.00 | +216.3K | 280.9K | +335% | $0 |
| I | 2022-05-23 | 2022-05-19 | QNCX | Lamond David | Dir | A - Grant | — | +200.0K | 1.73M | +13% | — |
| D | 2022-05-23 | 2022-05-19 | QNCX | Thye Dirk | CEO, Dir | A - Grant | — | +64.6K | 64.6K | New | — |
| D | 2022-05-23 | 2022-05-19 | QNCX | Smith Karen L. | Chief Medical Off | A - Grant | — | +24.3K | 24.3K | New | — |
| D | 2022-05-23 | 2022-05-19 | QNCX | Hannah Brendan | Chief Business Off | A - Grant | — | +16.2K | 16.2K | New | — |
| D | 2022-05-23 | 2022-05-19 | QNCX | Low Philip S | Dir | A - Grant | — | +455.3K | 455.3K | New | — |
| DI | 2022-05-23 | 2022-05-19 | QNCX | Low Philip S | Dir | A - Grant | — | +64.0K | 64.0K | New | — |
| 2022-03-04 | 2022-03-03 | QNCX | Detke Michael J. | Chief Medical Off | A - Grant | $0.00 | +140.0K | 140.0K | New | $0 | |
| 2022-03-04 | 2022-03-03 | QNCX | Holsinger Leslie | EVP, Preclinical Development | A - Grant | $0.00 | +155.5K | 159.0K | +4,443% | $0 | |
| 2022-03-04 | 2022-03-03 | QNCX | McDowell Caryn Gordon | Chief Legal, Adm. Off | A - Grant | $0.00 | +140.0K | 140.0K | New | $0 | |
| 2022-03-04 | 2022-03-03 | QNCX | Monohon Ted | CAO, VP | A - Grant | $0.00 | +34.0K | 34.0K | New | $0 | |
| 2022-03-04 | 2022-03-03 | QNCX | LOWE CHRISTOPHER P. | COO, CFO, Interim CEO | A - Grant | $0.00 | +175.0K | 265.0K | +194% | $0 | |
| D | 2021-11-19 | 2021-11-18 | QNCX | Lynch Casey | CEO, Dir | M - OptEx | $0.46 | +60.0K | 109.9K | +120% | +$27.6K |
| D | 2021-11-16 | 2021-11-16 | QNCX | LOWE CHRISTOPHER P. | COO, CFO | M - OptEx | $2.23 | +30.0K | 90.0K | +50% | +$66.9K |
| I | 2021-11-12 | 2021-11-12 | QNCX | Dominy Stephen S. | CSO, Dir | P - Purchase | $14.40 | +763 | 1.22M | +0.1% | +$11.0K |
| D | 2021-10-12 | 2021-10-08 | QNCX | McLoughlin Margaret | Dir | S - Sale+OE | $88.93 | -1,000 | 0 | -100% | -$88.9K |
| D | 2021-10-12 | 2021-10-08 | QNCX | McLoughlin Margaret | Dir | M - OptEx | $17.00 | +1,000 | 1,000 | New | +$17.0K |
| D | 2021-10-07 | 2021-10-05 | QNCX | LOWE CHRISTOPHER P. | COO, CFO | S - Sale+OE | $98.50 | -4,963 | 60.0K | -8% | -$488.9K |
| D | 2021-10-07 | 2021-10-05 | QNCX | LOWE CHRISTOPHER P. | COO, CFO | M - OptEx | $54.85 | +4,963 | 65.0K | +8% | +$272.2K |
| DM | 2021-08-18 | 2021-08-16 | QNCX | LOWE CHRISTOPHER P. | COO, CFO | S - Sale+OE | $95.31 | -22.0K | 33.2K | -40% | -$2.10M |
| DM | 2021-08-18 | 2021-08-16+ | QNCX | LOWE CHRISTOPHER P. | COO, CFO | M - OptEx | $2.23 | +52.0K | 52.0K | New | +$116.0K |
| DM | 2021-08-18 | 2021-08-16 | QNCX | McLoughlin Margaret | Dir | S - Sale+OE | $95.44 | -6,000 | 0 | -100% | -$572.6K |
| D | 2021-08-18 | 2021-08-16 | QNCX | McLoughlin Margaret | Dir | M - OptEx | $17.00 | +6,000 | 6,000 | New | +$102.0K |
| D | 2021-08-12 | 2021-08-10 | QNCX | Detke Michael J. | Chief Medical Off | S - Sale+OE | $100.00 | -10.0K | 0 | -100% | -$1.00M |
| D | 2021-08-12 | 2021-08-10 | QNCX | Detke Michael J. | Chief Medical Off | M - OptEx | $2.23 | +10.0K | 10.0K | New | +$22.3K |
| DM | 2021-07-07 | 2021-07-06+ | QNCX | Detke Michael J. | Chief Medical Off | M - OptEx | $2.23 | +30.0K | 17.4K | New | +$66.9K |
| DM | 2021-07-07 | 2021-07-06+ | QNCX | Detke Michael J. | Chief Medical Off | S - Sale+OE | $54.04 | -58.3K | 523 | -99% | -$3.15M |
Purchase Sale Sale after option exercise All abbreviations